BACKGROUND: We examined the effects and cost-effectiveness of 4 strategies of circumcision in a resource-rich setting (Australia) in a population of men who have sex with men (MSM). METHOD: We created a dynamic mathematical transmission model and performed an economic analysis to estimate the costs, outcomes, and cost-effectiveness of different strategies, compared with those of the status quo. Strategies included circumcision of all MSM at age 18 years, circumcision of all MSM aged 35-44 years, circumcision of all insertive MSM aged 18 years, and circumcision of all MSM aged 18 years . All costs are reported in US dollars, with a cost-effectiveness threshold of $42,000 per quality-adjusted life-year. RESULTS: We find that 2%-5% of human immunodeficiency virus (HIV) infections would be averted per year, with initial costs ranging from $3.6 million to $95.1 million, depending on the strategy. The number of circumcisions needed to prevent 1 HIV infection would range from 118 through 338. Circumcision of predominately insertive MSM would save $21.7 million over 25 years with a $62.2 million investment. Strategies to circumcise 100% of all MSM and to circumcise MSM aged 35-44 years would be cost-effective; the latter would require a smaller investment. The least cost-effective approach is circumcision of young MSM close to their sexual debut. Results are very sensitive to assumptions about the cost of circumcision, the efficacy of circumcision, sexual preferences, and behavioral disinhibition. CONCLUSIONS: Circumcision of adult MSM may be cost-effective in this resource-rich setting. However, the intervention costs are high relative to the costs spent on other HIV prevention programs.
BACKGROUND: We examined the effects and cost-effectiveness of 4 strategies of circumcision in a resource-rich setting (Australia) in a population of men who have sex with men (MSM). METHOD: We created a dynamic mathematical transmission model and performed an economic analysis to estimate the costs, outcomes, and cost-effectiveness of different strategies, compared with those of the status quo. Strategies included circumcision of all MSM at age 18 years, circumcision of all MSM aged 35-44 years, circumcision of all insertive MSM aged 18 years, and circumcision of all MSM aged 18 years . All costs are reported in US dollars, with a cost-effectiveness threshold of $42,000 per quality-adjusted life-year. RESULTS: We find that 2%-5% of human immunodeficiency virus (HIV) infections would be averted per year, with initial costs ranging from $3.6 million to $95.1 million, depending on the strategy. The number of circumcisions needed to prevent 1 HIV infection would range from 118 through 338. Circumcision of predominately insertive MSM would save $21.7 million over 25 years with a $62.2 million investment. Strategies to circumcise 100% of all MSM and to circumcise MSM aged 35-44 years would be cost-effective; the latter would require a smaller investment. The least cost-effective approach is circumcision of young MSM close to their sexual debut. Results are very sensitive to assumptions about the cost of circumcision, the efficacy of circumcision, sexual preferences, and behavioral disinhibition. CONCLUSIONS: Circumcision of adult MSM may be cost-effective in this resource-rich setting. However, the intervention costs are high relative to the costs spent on other HIV prevention programs.
Authors: Narat Punyacharoensin; William John Edmunds; Daniela De Angelis; Richard Guy White Journal: Eur J Epidemiol Date: 2011-09-20 Impact factor: 8.082
Authors: Chen Zhang; David F Penson; Han-Zhu Qian; Glenn F Webb; Jie Lou; Brian E Shephard; Yu Liu; Sten H Vermund Journal: Int J STD AIDS Date: 2019-03-19 Impact factor: 1.359
Authors: Brian J Morris; Jake H Waskett; Joya Banerjee; Richard G Wamai; Aaron A R Tobian; Ronald H Gray; Stefan A Bailis; Robert C Bailey; Jeffrey D Klausner; Robin J Willcourt; Daniel T Halperin; Thomas E Wiswell; Adrian Mindel Journal: BMC Pediatr Date: 2012-02-28 Impact factor: 2.125
Authors: Wim Delva; David P Wilson; Laith Abu-Raddad; Marelize Gorgens; David Wilson; Timothy B Hallett; Alex Welte Journal: PLoS Med Date: 2012-07-10 Impact factor: 11.069
Authors: Steven M Goodreau; Nicole B Carnegie; Eric Vittinghoff; Javier R Lama; Jonathan D Fuchs; Jorge Sanchez; Susan P Buchbinder Journal: PLoS One Date: 2014-07-30 Impact factor: 3.240